Science Minister Supports National Life Science Skills Initiative
Drug Discovery Today
MARCH 28, 2022
Science Minister George Freeman says life sciences have an essential part to play in creating the economy and ecosystem of tomorrow.
Sat.Mar 26, 2022 - Fri.Apr 01, 2022
113 
How the Medicaid Copay Accumulator Rule Will Hurt Prescription Affordability
Drug Channels
APRIL 1, 2022
Today’s guest post comes from Fauzea Hussain, Vice President of Public Policy at McKesson. Fauzea succinctly describes the complicated and contradictory aspects of the Centers for Medicare & Medicaid Services' Final Rule on Best Price, a.k.a. the Medicaid copay accumulator rule. She then outlines how the rule, if implemented, is likely to hurt patients.
Join 15,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
New Landscape for the Old Pandemic
Eye on FDA
MARCH 30, 2022
Tectonic pandemic plates are shifting respecting the COVID-19 pandemic. For weeks now we have been watching caseloads in the United States broadly fall. It feels as if we are indeed shifting gears. There are other moving parts that are in motion as well. It is a fundamental re-shifting of the landscape. And there are consequences. First, government funding supporting access to vaccination and treatment for COVID has run out and so far, is not replenished.
Which pharmaceutical companies have the most SPCs in Ireland?
Drug Patent Watch
APRIL 1, 2022
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Ireland. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Ireland? appeared first on DrugPatentWatch - Make Better Decisions.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Tryp Therapeutics Initiates Enrollment for Binge Eating Disorder Study in Partnership with University of Florida
Drug Discovery Today
MARCH 28, 2022
Phase 2 study is the first approved by the FDA and DEA to test psychedelic therapies in the area of binge eating disorders
PBM Industry Update: Trends, Controversies, and Outlook (NEW Live Video Webinar)
Drug Channels
MARCH 29, 2022
Dr. Adam J. Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for a new video webinar: PBM Industry Update: Trends, Controversies, and Outlook. Broadcast live on April 22, 2022 , from 12:00 p.m. to 1:30 p.m. ET This page describes the event and explains how to purchase a registration to participate in the event.
Signup to get articles personalized to your interests!
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
More Trending
New patent for Sarepta Theraps drug AMONDYS 45
Drug Patent Watch
APRIL 1, 2022
Annual Drug Patent Expirations for AMONDYS+45 Amondys 45 is a drug marketed by Sarepta Theraps Inc and is included in one NDA. It is available from one supplier. There are…. The post New patent for Sarepta Theraps drug AMONDYS 45 appeared first on DrugPatentWatch - Make Better Decisions.
The Current issue of “The view from here” is concerned with Epigenetics
Drug Discovery Today
MARCH 30, 2022
The topic of this month’s newsletter from Drug Discovery Today is “Epigenetics”.
Informa Connect’s Medicaid & Government Pricing Congress
Drug Channels
MARCH 28, 2022
Informa Connect’s Medicaid & Government Pricing Congress. Hybrid Event In-Person: May 23-25, 2022, Philadelphia, PA | Virtual: June 1-2, 2022 www.informaconnect.com/medicaid-government-pricing. Don’t miss the Medicaid & Government Pricing Congress , coming up May 23-25, 2022 (in-person in Philadelphia) and June 1-2, 2022 (virtually)! You'll be part of the important discussions surrounding the critical policy updates and approaches to effectively contract, report and comply with state and
EUROAPI listing on Euronext Paris expected on May 6, 2022
The Pharma Data
MARCH 31, 2022
French AMF approved EUROAPI’s listing prospectus EUROAPI first day of trading expected to occur on May 6, 2022 subject to the approval of the Distribution by the Ordinary and Extraordinary Shareholders’ Meeting to be held on May 3, 2022 Sanofi will host today a dedicated Capital Markets Day at 1:30 pm CET to present EUROAPI’s business in greater detail The Distribution ratio will be one (1) EUROAPI share per twenty three (23) Sanofi shares After the Distribution, Sanofi has confirmed its intenti
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
New patent for Catalyst Pharms drug FIRDAPSE
Drug Patent Watch
APRIL 1, 2022
Annual Drug Patent Expirations for FIRDAPSE Firdapse is a drug marketed by Catalyst Pharms and is included in one NDA. It is available from one supplier. There are two patents…. The post New patent for Catalyst Pharms drug FIRDAPSE appeared first on DrugPatentWatch - Make Better Decisions.
Pairing 3D Organoids with High-Content Imaging Can Develop Clear Views of Complex Cellular Systems
Crown Bioscience
MARCH 31, 2022
This post explores the benefits of combining high-content imaging (HCI) and high-content analysis (HCA) with 3D in vitro tumor organoids for drug discovery and validation studies. An increasing number of large in vitro screening studies are showing that novel clinically relevant biomarkers of drug response and important drug effects can be discovered by probing a wider array of cellular parameters combined with dose–response assessments.
Drug Channels News Roundup, March 2022: UM and Health Equity, Insurers ? White Bagging, Biosimilar Boom, A New Angle on Copay Support, and the Pharmacy Metaverse
Drug Channels
MARCH 31, 2022
Ah, it’s finally spring in downtown Philadelphia, our home base. (Photographic evidence on your right.) Along with sunshine and fine weather, this vernal equinox has ushered in a crop of new and noteworthy stories: Health inequities in utilization management Insurers compute big white bagging savings The biosimilar boom accelerates The patient upside of manufacturers’ copay support Whoa.
New Janssen Initiative Aims to Advance Equitable Care and Address Hidden Threat of Amputation Related to Peripheral Artery Disease (PAD)
The Pharma Data
MARCH 31, 2022
Through Save Legs. Change Lives. ™, Janssen seeks to elevate PAD research, collaboration, education and screening for communities placed at increased risk of cardiovascular disease. The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the launch of Save Legs. Change Lives.™ Spot Peripheral Artery Disease Now, a multi-year initiative aimed at creating urgency and action to address the hidden threat of peripheral artery disease (PAD)-related amputation, with an initial fo
Deliver Fast, Flexible Clinical Trial Insights with Spotfire
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
New patent for Nalpropion drug CONTRAVE
Drug Patent Watch
APRIL 1, 2022
Annual Drug Patent Expirations for CONTRAVE Contrave is a drug marketed by Nalpropion and is included in one NDA. It is available from three suppliers. There are eighteen patents protecting…. The post New patent for Nalpropion drug CONTRAVE appeared first on DrugPatentWatch - Make Better Decisions.
The Difference Between Social Anxiety and General Anxiety
Olympian Clinical Research
MARCH 31, 2022
Anxiety is the most common mental illness in the United States, affecting over 40 million adults every year. With anxiety at an all-time high as we live through a pandemic and an increasingly globalized and technologically advanced world, it can be challenging to understand what type of anxiety you may be experiencing. The most common types of anxiety are social and general anxiety, but how can you tell the difference?
Clustering Fragment Screening Hits With a Self-Organizing Map
Practical Cheminformatics
MARCH 28, 2022
Clustering Fragment Screening Hits With a Self-Organizing Map (SOM) In a paper, " Fragment binding to the Nsp3 macrodomain of SARS-CoV-2 identified through crystallographic screening and computational docking ", published last year by scientists from UCSF and the Diamond Light Source, the authors reported more than 200 structures of fragments bound to the Nsp3 macrodomain of SARS-CoV-2.
NIH begins clinical trial evaluating second COVID-19 booster shots in adults
The Pharma Data
MARCH 31, 2022
A Phase 2 clinical trial evaluating various additional COVID-19 booster shots has begun enrolling adult participants in the United States. The trial aims to understand if different vaccine regimens – prototype and variant vaccines alone and in combinations – can broaden immune responses in adults who already have received a primary vaccination series and a first booster shot.
Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Which pharmaceutical companies have the most capsule dosed drugs?
Drug Patent Watch
MARCH 31, 2022
This chart shows the pharmaceutical companies with the most capsule dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most capsule dosed drugs…. The post Which pharmaceutical companies have the most capsule dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.
Enthalpic fragments
Molecular Design
MARCH 31, 2022
Enthalpy-driven binding has been presented as a rationale for screening fragments although some have argued that thermodynamic signature is actually a 'red herring' in the context of drug discovery. Binding of a ligand grown from a fragment hit incurs a translational entropy penalty that is similar to that of the original fragment hit and it is therefore it is hardly surprising that synthetic elaboration results in binding that is more driven by entropy.
Latest news on drug repurposing in oncology #15
The Anticancer Fund
APRIL 1, 2022
1 April 2022 Language EN Drug repurposing is a strategy for identifying new uses for approved drugs, outside the scope of the original indication. It is one of the focus areas of the Anticancer Fund. Below, we have listed recent findings about the repurposing of generic drugs in oncology. Our intention is to help bring these findings to the attention of the broader cancer research community.
Sanofi successfully priced an inaugural sustainability-linked bond indexed on access to medicines
The Pharma Data
MARCH 31, 2022
Sanofi successfully priced yesterday, March 30, 2022, its offering of a dual-tranche EUR 1.5 billion of notes (the “Notes”). It comprises an inaugural issue of sustainability-linked bond for a nominal amount of EUR 650 million of notes, tied to Sanofi’s commitment to improve access to essential medicines in low- and lower-middle-income countries via its global health nonprofit unit.
New patent expiration for Schering drug NOXAFIL
Drug Patent Watch
MARCH 31, 2022
Annual Drug Patent Expirations for NOXAFIL Noxafil is a drug marketed by Merck Sharp Dohme, Schering, and Msd Merck Co and, and is included in four NDAs. It is available…. The post New patent expiration for Schering drug NOXAFIL appeared first on DrugPatentWatch - Make Better Decisions.
Paper on drug discovery equipment
Sygnature Discovery
MARCH 31, 2022
Take a look at this new paper on drug discovery equipment
DOJ Investigates $250 Million in U.S. Sales of Counterfeit Drugs Using Fake DSCSA Pedigrees
Policy Prescription
APRIL 1, 2022
The U.S. Department of Justice, according to Seeking Alpha , is investigating the sale and distribution of counterfeit drugs in the U.S. that may have amounted to a quarter-billion dollars. The investigation comes about two months after The Wall Street Journal reported on a lawsuit filed by Gilead Sciences alleging a massive breach in the U.S. drug supply chain consisting of $250 million in counterfeit HIV drugs that were sold throughout the U.S. from licensed pharmacies to American patien
Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer
The Pharma Data
MARCH 29, 2022
If approved, the Opdivo regimen would be the first and only immunotherapy-based option authorized for use before surgery in patients with non-small cell lung cancer ( NSCLC) in the European Union. Application based on CheckMate -816, the only Phase 3 trial to demonstrate improved event-free survival and pathologic complete response with an immunotherapy-based combination in the neoadjuvant setting of NSCLC.
Which pharmaceutical drugs have the most drug patents in Luxembourg?
Drug Patent Watch
MARCH 30, 2022
This chart shows the drugs with the most patents in Luxembourg. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Luxembourg? appeared first on DrugPatentWatch - Make Better Decisions.
Eleventh Circuit Disapproves Non-Intended Use Salami Slicing
Drug & Device Law
MARCH 31, 2022
The Orthopedic Bone Screw would never have occurred – and Bexis might never have found his way to prescription medical product liability litigation – if not for the Kessler-era FDA’s ill-considered salami slicing of the “intended use” of that product. In that instance, the FDA had limited its cleared “intended use” to disc spaces in the lowest part of the spine, while essentially identical, equally safe placement in adjacent disc spaces was off-label (and also the medical standard of care).
New patent for HIKMA drug KLOXXADO
Drug Patent Watch
MARCH 30, 2022
Annual Drug Patent Expirations for KLOXXADO Kloxxado is a drug marketed by Hikma and is included in one NDA. It is available from one supplier. There are two patents protecting…. The post New patent for HIKMA drug KLOXXADO appeared first on DrugPatentWatch - Make Better Decisions.
Boehringer Ingelheim selects Veeva Development Cloud worldwide to bring innovative therapies to patients faster
The Pharma Data
MARCH 29, 2022
With Veeva Development Cloud, Boehringer Ingelheim aims to establish a connected technology landscape for agile collaboration that can accelerate the development of novel medicines Transformation focuses on reducing complexity and developing an innovative, digital culture to better understand and address unmet medical needs. Boehringer Ingelheim and Veeva Systems (NYSE: VEEV) today announce Boehringer Ingelheim’s selection of Veeva Development Cloud to drive end-to-end processes and seamless inf
Sanofi and IGM Biosciences Announce Collaboration Agreement for Oncology, Immunology and Inflammation Targets
The Pharma Data
MARCH 29, 2022
* Companies to leverage proprietary IgM antibody technology platform to discover agonists against three oncology targets and three immunology/inflammation targets. * Collaboration to create, develop, manufacture and commercialize new class of potential therapeutics combining the superior features of multi-valent IgM antibodies over conventional IgG antibodies for stimulating cell surface receptors. * IGM to receive $150 million upfront payments, potentially over $6 billion in aggregate developme
Ondexxya approved in Japan for reversal of acute major bleeds in patients on Factor Xa inhibitors
The Pharma Data
MARCH 29, 2022
Ondexxya (andexanet alfa)has been approved in Japan for patients treated with the Factor Xa (FXa) inhibitors apixaban, rivaroxaban or edoxaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding. The approval by the Japanese Ministry of Health, Labour and Welfare was based on positive results from the ANNEXA-4 Phase III clinical trial showing Ondexxya rapidly and markedly reversed anti-FXa activity in patients with acute major bleeding.
FDA Authorizes Second Booster Dose of Two COVID-19 Vaccines for Older and Immunocompromised Individuals
The Pharma Data
MARCH 29, 2022
Today, the U.S. Food and Drug Administration authorized a second booster dose of either the Pfizer-BioNTech or the Moderna COVID-19 vaccines for older people and certain immunocompromised individuals. The FDA previously authorized a single booster dose for certain immunocompromised individuals following completion of a three-dose primary vaccination series.
Let's personalize your content